Critical Therapeutics, Inc., a biotech focused on developing drugs to regulated the inflammatory response associated with asthma and critical care diseases, filed with the SEC to go public on Friday. The Cambridge, MA based company has selected SG Cowen as the lead underwriter for the deal. Terms and timing have not yet been determined.
